Source: Reuters U.S. prosecutors have opened a criminal investigation into Valeant Pharmaceuticals International Inc (VRX.N) over whether it hid from insurers its relationship with a specialty pharmacy that helped boost its drug sales, the Wall Street Journal reported on Wednesday. Lawyers at the U.S. Attorney's Manhattan office are trying to…...

Source: Real Money Valeant Pharmaceuticals' (VRX) new CEO Joseph Papa may have spoken too soon in his pledge to begin to curb drug prices that had been hiked to controversial levels -- especially as the drugmaker's roughly $31 billion debt package did not come without strings attached. Lender-friendly covenants, such…...

Source: CNBC Journey Medical Corporation, a subsidiary of Fortress Biotech, Inc. (FBIO), launched the first two prescription products in its dermatology franchise, Luxamend™ Wound Cream and Ceracade™ Skin Barrier Emulsion. Both products will be showcased at the 2016 American Academy of Dermatology (AAD) Summer Meeting (Booth #622) to be held…...

Source: The Wall Street Journal Michael Pearson has sold nearly $100 million of his stock in Valeant Pharmaceuticals International Inc. in the past two weeks, according to securities filings, following his firing as the troubled drugmaker’s chief executive in March. Mr. Pearson sold 288,441 shares on June 30 for $5.8…...

Source: Galderma, a global leader focused on medical solutions in skin health, today announced that its U.S. affiliate, Galderma Laboratories, L.P. received approval from the U.S. Food and Drug Administration (FDA) for Differin® Gel (adapalene gel 0.1%) as an over-the-counter (OTC) treatment for acne. This approval makes Differin® Gel the…...

Source: LEO Pharma has entered a strategic partnership with AstraZeneca for new medicines for atopic dermatitis and psoriasis, major skin diseases with a significant unmet medical need. Under the move, LEO gains a the global licence to AZ' tralokinumab in skin diseases and an exclusive licence to brodalumab in Europe.…...

Source: Teva’s massive agreement to buy Allergan’s generics business continues to ripple its way through the industry. Australia’s Mayne Pharma has scooped up 42 products from the two companies, which are intent on winning antitrust clearance for their $40.5 billion deal. Though smaller in size, Mayne's $652 million buy is…...

Source: Business Wire Pfizer Inc. (NYSE:PFE) today announced that it has completed its acquisition of Anacor Pharmaceuticals, Inc. Under the terms of the transaction, each outstanding share of Anacor common stock has been converted into the right to receive $99.25 net in cash (without interest but subject to required withholding…...

Source: By Zeba Siddiqui MUMBAI (Reuters) - India's largest drugmaker Sun Pharmaceutical Industries is banking on the launch of newer and more complex products to offset rising competition in its lucrative U.S. dermatology business, its U.S. chief said. The world's fifth-largest maker of generic drugs was the first among its…...

Source: FierceMedicalDevice Healthcare growth investor Essex Woodlands has backed Suneva Medical with a new $25 million financing aimed at expanding its marketing of the only FDA-approved dermal filler that's specifically indicated for smile lines or facial acne scars. In January 2015, Suneva's Bellafill was approved by the agency to treat…...